Linda Ottoboni

Linda Ottoboni

Auto-generated profile, based on publicly available information

Linda Ottoboni

Dino Ferrari Center, Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ICInternational MS Genetics Consortium
International MS Genetics Consortium
PJPhilip L De Jager
Philip L De Jager
XJXiaoming Jia
Xiaoming Jia
JWJoanne Wang
Joanne Wang
PBPaul I W de Bakker
Paul I W de Bakker
JOJorge R Oksenberg
Jorge R Oksenberg

1 July 2005 in Nature
Verified
Journal Article
Closed access
PDF file
Stefano PluchinoStefano Pluchino
Stefano Pluchino
LZLucia Zanotti
Lucia Zanotti
BRBarbara Rossi
Barbara Rossi
EBElena Brambilla
Elena Brambilla
LOLinda Ottoboni
Linda Ottoboni
GMGianvito Martino
Gianvito Martino

23 May 2013 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
TIThe Alzheimer Disease Neuroimaging Initiative
The Alzheimer Disease Neuroimaging Initiative
EBElizabeth M Bradshaw
Elizabeth M Bradshaw
LCLori B Chibnik
Lori B Chibnik
BKBrendan T Keenan
Brendan T Keenan
LOLinda Ottoboni
Linda Ottoboni
PJPhilip L De Jager
Philip L De Jager
Genome-wide association studies have identified CD33 as an Alzheimer's disease susceptibility locus. Here, the authors show that the CD33 risk allele is associated with altered myeloid function, microglial activation and in vivo amyloid pathology. In our functional dissection of the CD33 Alzheimer's disease susceptibility locus, we found that the rs3865444C risk allele was associated with greater cell surface expression of CD33 in the monocytes (t50 = 10.06, Pjoint = 1.3 × 10−13) of young and older individuals. It was also associated with diminished internalization of amyloid-β 42 peptide, accumulation of neuritic amyloid pathology and fibrillar amyloid on in vivo imaging, and increased numbers of activated human microglia.

23 November 2008 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Paolo FabenePaolo Fabene
Paolo Fabene
GMGraciela Navarro Mora
Graciela Navarro Mora
MMMarianna Martinello
Marianna Martinello
BRBarbara Rossi
Barbara Rossi
FMFlavia Merigo
Flavia Merigo
GCGabriela Constantin
Gabriela Constantin

31 March 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
PJPhilip L. De Jager
Philip L. De Jager
CBClare M. Baecher-Allan
Clare M. Baecher-Allan
LMLisa M. Maier
Lisa M. Maier
AAAriel T. Arthur
Ariel T. Arthur
LOLinda Ottoboni
Linda Ottoboni
DHDavid A. Hafler
David A. Hafler
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system associated with demyelination and axonal loss. A whole genome association scan suggested that allelic variants in the CD58 gene region, encoding the costimulatory molecule LFA-3, are associated with risk of developing MS. We now report additional genetic evidence, as well as resequencing and fine mapping of the CD58 locus in patients with MS and control subjects. These efforts identify a CD58 variant that provides further evidence of association with MS ( P = 1.1 × 10 −6 , OR 0.82) and the single protective effect within the CD58 locus is captured by the rs2300747 G allele. This protective rs2300747 G allele is associated with a dose-dependent increase in CD58 mRNA expression in lymphoblastic cell lines ( P = 1.1 × 10 −10 ) and in peripheral blood mononuclear cells from MS subjects ( P = 0.0037). This protective effect of enhanced CD58 expression on circulating mononuclear cells in patients with MS is supported by finding that CD58 mRNA expression is higher in MS subjects during clinical remission. Functional investigations suggest a potential mechanism whereby increases in CD58 expression, mediated by the protective allele, up-regulate the expression of transcription factor FoxP3 through engagement of the CD58 receptor, CD2, leading to the enhanced function of CD4 + CD25 high regulatory T cells that are defective in subjects with MS.

1 January 2004 in Immunity
Verified
Journal Article
Closed access
CGCinzia Giagulli
Cinzia Giagulli
ESElio Scarpini
Elio Scarpini
LOLinda Ottoboni
Linda Ottoboni
SNShuh Narumiya
Shuh Narumiya
EBEugene C Butcher
Eugene C Butcher
CLCarlo Laudanna
Carlo Laudanna